Other Information
+Added: | June 30, 2024, Form 10-Q
Exhibit Description
4 unchanged sentences
Amendment to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on March 21, 2023).
−Removed: Sales Agreement dated October 27, 2023, by and between IGC Pharma, Inc.
−Removed: and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 27, 2023).
Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.
10 unchanged sentences
Furnished herewith.
−Removed: | December 31, 2023, Form 10-Q
+Added: | June 30, 2024, Form 10-Q
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IGC PHARMA, INC.
−Removed: February 14, 2024
+Added: August 7, 2024
/s/ Ram Mukunda
1 unchanged sentence
(Principal Executive Officer)
−Removed: February 14, 2024
+Added: August 7, 2024
/s/ Claudia Grimaldi
2 unchanged sentences
(Principal Financial Officer)
−Removed: | December 31, 2023, Form 10-Q
+Added: | June 30, 2024, Form 10-Q
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.